Reuters: IPOX® CEO Schuster Comments on Medline's 'Blockbuster' $55 Billion IPO Target

In a recent Reuters article, IPOX® CEO Josef Schuster provided critical analysis on Medline's target valuation of up to $55.3 billion for its upcoming U.S. initial public offering. The medical supplies giant is seeking to raise approximately $5.37 billion by offering 179 million shares priced between $26 and $30, a move that is expected to make this the largest IPO of 2025. The listing is viewed as a significant bellwether for the broader financial markets as they head into 2026, particularly given the strong cornerstone investor interest of up to $2.35 billion from major firms including Baillie Gifford and Morgan Stanley's Counterpoint Global.

Dr. Schuster highlighted the strategic importance of this offering for the wider IPO landscape, noting that it serves as a litmus test for investor appetite beyond the technology sector:

"The reception to Medline's IPO will be crucial as it's set to re-test the market for IPOs in sectors other than crypto, AI and fintech, which thus far has been really strong."

Additionally, Dr. Schuster reflected on the company's prior IPO in the 1970s, the firm’s historical significance and its effective use of public markets to fuel expansion:

"The re-IPO is another step for a company which is really an amazing American growth story and where 'going public' has played a major role in funding growth."

Read the full article by Arasu Kannagi Basil on Reuters: Medical supply firm Medline targets $55 billion valuation in blockbuster IPO